CanadaBis Capital Inc.
CanadaBis Capital Inc. engages in the production and sale of recreational cannabis and cannabis extracts in Canada. It operates through two segments: Cultivation and Extraction. The company cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. It is also involved in the production and wholesale distribution of cannabis extract products th… Read more
CanadaBis Capital Inc. (CNADF) - Net Assets
Latest net assets as of October 2025: $7.80 Million USD
Based on the latest financial reports, CanadaBis Capital Inc. (CNADF) has net assets worth $7.80 Million USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($24.43 Million) and total liabilities ($16.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.80 Million |
| % of Total Assets | 31.91% |
| Annual Growth Rate | 18.21% |
| 5-Year Change | 335.08% |
| 10-Year Change | N/A |
| Growth Volatility | 76.73 |
CanadaBis Capital Inc. - Net Assets Trend (2020–2025)
This chart illustrates how CanadaBis Capital Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CanadaBis Capital Inc. (2020–2025)
The table below shows the annual net assets of CanadaBis Capital Inc. from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-07-31 | $7.92 Million | +6.91% |
| 2024-07-31 | $7.41 Million | +0.92% |
| 2023-07-31 | $7.34 Million | +178.86% |
| 2022-07-31 | $2.63 Million | +44.61% |
| 2021-07-31 | $1.82 Million | -46.96% |
| 2020-07-31 | $3.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CanadaBis Capital Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 145678400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (July 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $21.22 Million | 270.96% |
| Total Equity | $7.83 Million | 100.00% |
CanadaBis Capital Inc. Competitors by Market Cap
The table below lists competitors of CanadaBis Capital Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Arita Prima Indonesia Tbk
JK:APII
|
$2.82 Million |
|
DarkIris Inc. Class A Ordinary Shares
NASDAQ:DKI
|
$2.82 Million |
|
Sfinks Polska S.A.
WAR:SFS
|
$2.82 Million |
|
AIOS Tech Inc.
NASDAQ:AIOS
|
$2.83 Million |
|
Royal Hali Iplik Tekstil Mobilya Sanayi ve Ticaret AS
IS:ROYAL
|
$2.82 Million |
|
INDUSTRIAL MINERALS LTD
F:9ED
|
$2.82 Million |
|
Babylon Pump & Power Ltd
AU:BPP
|
$2.82 Million |
|
BIGBEN INTERACT.INH. EO 2
F:BX9
|
$2.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CanadaBis Capital Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,318,659 to 7,830,761, a change of 512,102 (7.0%).
- Net loss of 835,204 reduced equity.
- Other factors increased equity by 1,347,306.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-835.20K | -10.67% |
| Other Changes | $1.35 Million | +17.21% |
| Total Change | $- | 7.00% |
Book Value vs Market Value Analysis
This analysis compares CanadaBis Capital Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.11x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.49x to 1.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-07-31 | $0.03 | $0.06 | x |
| 2021-07-31 | $0.01 | $0.06 | x |
| 2022-07-31 | $0.02 | $0.06 | x |
| 2023-07-31 | $0.05 | $0.06 | x |
| 2024-07-31 | $0.05 | $0.06 | x |
| 2025-07-31 | $0.06 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CanadaBis Capital Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.94%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 3.13x
- Recent ROE (-10.67%) is above the historical average (-40.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -161.52% | -121.68% | 0.35x | 3.75x | $-5.72 Million |
| 2021 | -154.93% | -38.98% | 0.52x | 7.69x | $-2.85 Million |
| 2022 | 23.95% | 5.21% | 0.75x | 6.09x | $354.28K |
| 2023 | 61.30% | 20.00% | 0.97x | 3.17x | $3.72 Million |
| 2024 | -1.15% | -0.47% | 0.73x | 3.35x | $-815.93K |
| 2025 | -10.67% | -4.94% | 0.69x | 3.13x | $-1.62 Million |
Industry Comparison
This section compares CanadaBis Capital Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CanadaBis Capital Inc. (CNADF) | $7.80 Million | -161.52% | 2.13x | $2.82 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |